![MicroRNA-34 family: a potential tumor suppressor and therapeutic candidate in cancer | Journal of Experimental & Clinical Cancer Research | Full Text MicroRNA-34 family: a potential tumor suppressor and therapeutic candidate in cancer | Journal of Experimental & Clinical Cancer Research | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13046-019-1059-5/MediaObjects/13046_2019_1059_Fig3_HTML.png)
MicroRNA-34 family: a potential tumor suppressor and therapeutic candidate in cancer | Journal of Experimental & Clinical Cancer Research | Full Text
![Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine: Molecular Therapy - Nucleic Acids Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine: Molecular Therapy - Nucleic Acids](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/8c05b5c2-158d-4a4c-98c6-2aaa1ae3c01c/gr1_lrg.jpg)
Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine: Molecular Therapy - Nucleic Acids
![Frontiers | MicroRNA-34a: Potent Tumor Suppressor, Cancer Stem Cell Inhibitor, and Potential Anticancer Therapeutic | Cell and Developmental Biology Frontiers | MicroRNA-34a: Potent Tumor Suppressor, Cancer Stem Cell Inhibitor, and Potential Anticancer Therapeutic | Cell and Developmental Biology](https://www.frontiersin.org/files/Articles/640587/fcell-09-640587-HTML/image_m/fcell-09-640587-g001.jpg)
Frontiers | MicroRNA-34a: Potent Tumor Suppressor, Cancer Stem Cell Inhibitor, and Potential Anticancer Therapeutic | Cell and Developmental Biology
![RNA-targeted therapeutics in cancer clinical trials: Current status and future directions - Cancer Treatment Reviews RNA-targeted therapeutics in cancer clinical trials: Current status and future directions - Cancer Treatment Reviews](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2070383444/2067986306/gr1.jpg)
RNA-targeted therapeutics in cancer clinical trials: Current status and future directions - Cancer Treatment Reviews
![Recent progress in microRNA-based delivery systems for the treatment of human disease | ExRNA | Full Text Recent progress in microRNA-based delivery systems for the treatment of human disease | ExRNA | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs41544-019-0024-y/MediaObjects/41544_2019_24_Fig1_HTML.png)
Recent progress in microRNA-based delivery systems for the treatment of human disease | ExRNA | Full Text
![Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours | British Journal of Cancer Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours | British Journal of Cancer](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41416-020-0802-1/MediaObjects/41416_2020_802_Fig2_HTML.png)
Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours | British Journal of Cancer
![Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours | British Journal of Cancer Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours | British Journal of Cancer](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41416-020-0802-1/MediaObjects/41416_2020_802_Fig3_HTML.png)
Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours | British Journal of Cancer
![PDF) Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors PDF) Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors](https://www.researchgate.net/profile/Sinil-Kim-2/publication/311423596/figure/fig1/AS:614630770618369@1523550803429/figure-fig1_Q320.jpg)
PDF) Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors
![Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours | British Journal of Cancer Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours | British Journal of Cancer](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41416-020-0802-1/MediaObjects/41416_2020_802_Fig1_HTML.png)